108552
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
脑脊液中白细胞介素 - 20 受体 A 表达下调与烟雾病风险相关：基于炎症蛋白质组学图谱的分子特征分析
Authors Xia C, Liu B, Hu Y, Cheng H , Ye L
Received 10 June 2025
Accepted for publication 4 September 2025
Published 18 September 2025 Volume 2025:18 Pages 12961—12970
DOI https://doi.org/10.2147/JIR.S545941
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Ning Quan
Chengdong Xia,1,2 Bohang Liu,1 Yangchun Hu,1 Hongwei Cheng,1 Lei Ye1
1Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People’s Republic of China; 2Department of Neurosurgery, Lu’an Hospital of Traditional Chinese Medicine of Anhui Province, Lu’an, Anhui, People’s Republic of China
Correspondence: Hongwei Cheng, Email hongwei.cheng@ahmu.edu.cn Lei Ye, Email yelei@ahmu.edu.cn
Purpose: Moyamoya disease (MMD) is a cerebrovascular disorder with diverse clinical manifestations. Surgical revascularization is currently the optimal choice in the treatment of MMD; however, it could not prevent the progression of the disease. Inflammation and immunity factors have been reported to play the pivotal role in the pathogenesis of MMD, but there were still limited studies concerning the inflammatory landscape. Here, we aimed to investigate the molecular signatures of MMD to outline the inflammatory feature of MMD.
Patients and Methods: A total of 89 MMD patients and 93 healthy subjects were recruited for this study. We then divided all patients into screening cohort (15 MMD patients and 21 healthy subjects) and validation cohort (74 MMD patients and 72 healthy subjects). Proteomic analysis of the cerebrospinal fluid (CSF) was performed in the screening cohort, which contained 363 inflammation-related molecules. Then we used ELISA assay to validation of molecules of differential expression.
Results: We screened 192 inflammation-related proteins that were differentially expressed in the CSF of MMD patients. Among that, 191 proteins were upregulated, while IL-20RA were downregulated (p=0.042). The bioinformatic analysis found a potential inflammatory landscape of MMD, offering clues for pathogenetic and therapeutic targets in the mechanistic study. We then validated that downregulation of IL-20RA in CSF was associated with the risk of MMD in the validation cohort.
Conclusion: This study provided molecular signatures of MMD with a large-scale proteomic analysis of CSF. IL-20RA might be a key element in the pathogenesis of MMD.
Keywords: moyamoya disease, proteomics, IL-20RA, inflammation, angiogenesis
1Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People’s Republic of China; 2Department of Neurosurgery, Lu’an Hospital of Traditional Chinese Medicine of Anhui Province, Lu’an, Anhui, People’s Republic of China
Correspondence: Hongwei Cheng, Email hongwei.cheng@ahmu.edu.cn Lei Ye, Email yelei@ahmu.edu.cn
Purpose: Moyamoya disease (MMD) is a cerebrovascular disorder with diverse clinical manifestations. Surgical revascularization is currently the optimal choice in the treatment of MMD; however, it could not prevent the progression of the disease. Inflammation and immunity factors have been reported to play the pivotal role in the pathogenesis of MMD, but there were still limited studies concerning the inflammatory landscape. Here, we aimed to investigate the molecular signatures of MMD to outline the inflammatory feature of MMD.
Patients and Methods: A total of 89 MMD patients and 93 healthy subjects were recruited for this study. We then divided all patients into screening cohort (15 MMD patients and 21 healthy subjects) and validation cohort (74 MMD patients and 72 healthy subjects). Proteomic analysis of the cerebrospinal fluid (CSF) was performed in the screening cohort, which contained 363 inflammation-related molecules. Then we used ELISA assay to validation of molecules of differential expression.
Results: We screened 192 inflammation-related proteins that were differentially expressed in the CSF of MMD patients. Among that, 191 proteins were upregulated, while IL-20RA were downregulated (p=0.042). The bioinformatic analysis found a potential inflammatory landscape of MMD, offering clues for pathogenetic and therapeutic targets in the mechanistic study. We then validated that downregulation of IL-20RA in CSF was associated with the risk of MMD in the validation cohort.
Conclusion: This study provided molecular signatures of MMD with a large-scale proteomic analysis of CSF. IL-20RA might be a key element in the pathogenesis of MMD.
Keywords: moyamoya disease, proteomics, IL-20RA, inflammation, angiogenesis